Following a decline in 2010 net profit of 67%, GlaxoSmithKline Plc acted to support shareholder confidence by raising its dividend by 7% for the year and to launching a new long-term share repurchase programme that could see it buy back between £1 and 2 billion worth of its shares in 2011.
